|
AESCAP VENTURE MANAGEMENT
|
| On this site you find detailed information about
companies and institutions active in the Biotechnology (Biotech), Medical Technology (Medtech)
or Pharmaceutical (Pharma) industries, such as Aescap Venture Management. The Database informs you
about the product pipeline of a company, about financing rounds, investors, the technology
platform used etc. You can click on the company name below to see more detailed information. |
Aescap Venture is a venture capital company investing in private medical companies in Europe working on the treatment of human diseases. We help companies to shorten the timelines between invention and the actual market availability. Aescap typically invests in high-potential companies that are sufficiently mature to yield realistic product opportunities and cashflow from licensing deals. This involves investments in all phases of development with an emphasis on earlier stages. Aescap Venture’s added value is based on a multi-disciplinary team of best of breed investment partners. Each has a proven track record of success in the marketplace and the skills to coach entrepreneurs in accelerating the growth of their companies.
The fund size of Aescap Venture Fund I is €103 million. The founders of Aescap are Michiel de Haan, the founder and CEO of Atlas Venture until 2000 and Dinko Valerio PhD, the founder and former CEO of Crucell, a Euronext / NASDAQ-listed biotechnology company. Additional Partners are Patrick Krol MBA, a successful entrepreneur and expert in Life Science marketing and business development and Kreske Nickelsen MSc/MBA, previous Director at 3i, with 10 years of experience in European Life Science venture capital.
|
